Abvc biopharma provides vitargus update on phase ii site initiation visit conducted at ramathibodi hospital in thailand

Fremont, ca, april 06, 2023 (globe newswire) -- via newmediawire – abvc biopharma, inc. (nasdaq: abvc), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, today announced that vitargus® phase ii site initiation visit (siv) at ramathibodi hospital, faculty of medicine, mahidol university (th001) in thailand was successfully conducted on march 22, 2023. the siv was an organized meeting to discuss the phase ii study protocol with the principal investigator, duangnate rojanaporn, m.d. and begin training clinical personnel.
ABVC Ratings Summary
ABVC Quant Ranking